Daniel Braun

3.7k total citations · 3 hit papers
22 papers, 2.9k citations indexed

About

Daniel Braun is a scholar working on Immunology, Epidemiology and Dermatology. According to data from OpenAlex, Daniel Braun has authored 22 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Epidemiology and 4 papers in Dermatology. Recurrent topics in Daniel Braun's work include Psoriasis: Treatment and Pathogenesis (7 papers), Herpesvirus Infections and Treatments (5 papers) and Dermatology and Skin Diseases (4 papers). Daniel Braun is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (7 papers), Herpesvirus Infections and Treatments (5 papers) and Dermatology and Skin Diseases (4 papers). Daniel Braun collaborates with scholars based in United States, Canada and Germany. Daniel Braun's co-authors include G Dominguez, Philip E. Pellett, Gregory S. Cameron, J. Erickson, Kim Papp, Kristian Reich, Olawale Osuntokun, Brian J. Nickoloff, Roberta J. Secrest and Susan Ball and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Clinical Microbiology Reviews.

In The Last Decade

Daniel Braun

22 papers receiving 2.9k citations

Hit Papers

Comparison of ixekizumab with etanercept or placebo in mo... 2015 2026 2018 2022 2015 2016 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    2015 658 citations C.E.M. Griffiths, Kristian Reich et al. The Lancet profile →
  2. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine profile →
  3. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Braun United States 15 2.0k 967 663 661 442 22 2.9k
Shinichi Imafuku Japan 25 1.2k 0.6× 1.2k 1.3× 464 0.7× 394 0.6× 135 0.3× 182 2.3k
Katrin Witte Germany 22 1.7k 0.9× 1.1k 1.1× 232 0.3× 480 0.7× 116 0.3× 32 2.8k
Silvia Helou Argentina 10 1.3k 0.7× 727 0.8× 332 0.5× 326 0.5× 212 0.5× 16 1.7k
Aarnoud Huissoon United Kingdom 27 1.0k 0.5× 366 0.4× 380 0.6× 249 0.4× 273 0.6× 68 2.7k
Abhishek V. Garg United States 16 1.7k 0.9× 353 0.4× 225 0.3× 408 0.6× 142 0.3× 17 2.7k
Haifa H. Jabara United States 33 3.3k 1.7× 380 0.4× 345 0.5× 269 0.4× 176 0.4× 54 4.6k
Samuele E. Burastero Italy 29 1.5k 0.8× 473 0.5× 268 0.4× 216 0.3× 114 0.3× 89 3.2k
Melanie A. Kleinschek United States 15 2.5k 1.3× 261 0.3× 141 0.2× 420 0.6× 171 0.4× 18 3.3k
Diane U. Leong United States 10 907 0.5× 268 0.3× 278 0.4× 516 0.8× 147 0.3× 12 2.2k
Christiane Pfeiffer Germany 22 1.4k 0.7× 362 0.4× 521 0.8× 248 0.4× 64 0.1× 39 2.5k

Countries citing papers authored by Daniel Braun

Since Specialization
Citations

This map shows the geographic impact of Daniel Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Braun more than expected).

Fields of papers citing papers by Daniel Braun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Braun. The network helps show where Daniel Braun may publish in the future.

Co-authorship network of co-authors of Daniel Braun

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Braun. A scholar is included among the top collaborators of Daniel Braun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Braun. Daniel Braun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Braun, Daniel, Jens Schlossmann, & Ekkehard Haen. (2021). Asymmetric dimethylarginine in psychiatric disorders. Psychiatry Research. 300. 113901–113901. 6 indexed citations
2.
Papp, Kim, H. Bachelez, Andrew Blauvelt, et al.. (2017). Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. British Journal of Dermatology. 177(6). 1537–1551. 44 indexed citations
3.
Mease, Philip J., Désirée van der Heijde, Christopher T. Ritchlin, et al.. (2016). Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases. 76(1). 79–87. 431 indexed citations breakdown →
4.
Papp, Kim, Robert Bissonnette, Mamitaro Ohtsuki, et al.. (2016). 059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials. Journal of Investigative Dermatology. 136(9). S170–S170. 2 indexed citations
5.
Gordon, Kenneth B., Andrew Blauvelt, Kim Papp, et al.. (2016). Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine. 375(4). 345–356. 650 indexed citations breakdown →
6.
Strober, Bruce, Craig L. Leonardi, Kim Papp, et al.. (2016). Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology. 76(3). 432–440.e17. 98 indexed citations
7.
Griffiths, C.E.M., Kristian Reich, Mark Lebwohl, et al.. (2015). Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 386(9993). 541–551. 658 indexed citations breakdown →
8.
Gordon, Kenneth B., Craig L. Leonardi, Mark Lebwohl, et al.. (2014). A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology. 71(6). 1176–1182. 87 indexed citations
9.
10.
Gill, Anne, Byron J. Hoogwerf, Simon Bruce, et al.. (2010). Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovascular Diabetology. 9(1). 6–6. 117 indexed citations
11.
Nicas, Thalia I., Michael L. Zeckel, & Daniel Braun. (1997). Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends in Microbiology. 5(6). 240–249. 29 indexed citations
12.
Braun, Daniel, G Dominguez, & Philip E. Pellett. (1997). Human herpesvirus 6.. Clinical Microbiology Reviews. 10(3). 521–567. 2 indexed citations
13.
Braun, Daniel, G Dominguez, & Philip E. Pellett. (1997). Human herpesvirus 6. Clinical Microbiology Reviews. 10(3). 521–567. 347 indexed citations
14.
Shanley, Charles J., Daniel Braun, Kimberly Brown, et al.. (1995). FULMINANT HEPATIC FAILURE SECONDARY TO HERPES SIMPLEX VIRUS HEPATITIS. Transplantation. 59(1). 145–149. 45 indexed citations
15.
Clark, Nina M., et al.. (1995). Primary Cutaneous Nocardia otitidiscaviarum Infection: Case Report and Review. Clinical Infectious Diseases. 20(5). 1266–1270. 36 indexed citations
16.
Braun, Daniel. (1995). Human Herpesvirus 6: Ubiquitous Virus, Emerging Pathogen. Infectious Diseases in Clinical Practice. 4(4). 258–266. 1 indexed citations
17.
Braun, Daniel. (1993). Zur Phänologie und Vertikalverteilung von Weberknechten an Kiefernstämmen. Arachnologische Mitteilungen Arachnology Letters. 5. 33–35. 1 indexed citations
18.
Braun, Daniel, Bernard Roizman, & Lenore Pereira. (1984). Characterization of post-translational products of herpes simplex virus gene 35 proteins binding to the surfaces of full capsids but not empty capsids. Journal of Virology. 49(1). 142–153. 84 indexed citations
19.
Braun, Daniel, W Batterson, & Bernard Roizman. (1984). Identification and genetic mapping of a herpes simplex virus capsid protein that binds DNA. Journal of Virology. 50(2). 645–648. 32 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinichi Imafuku Breakdown of academic impact, for papers by Katrin Witte Breakdown of academic impact, for papers by Silvia Helou Breakdown of academic impact, for papers by Aarnoud Huissoon Breakdown of academic impact, for papers by Abhishek V. Garg Breakdown of academic impact, for papers by Haifa H. Jabara Breakdown of academic impact, for papers by Samuele E. Burastero Breakdown of academic impact, for papers by Melanie A. Kleinschek Breakdown of academic impact, for papers by Diane U. Leong Breakdown of academic impact, for papers by Christiane Pfeiffer
Rankless by CCL
2026